Group 1 - The core viewpoint is that the innovative pharmaceutical sector is experiencing sustained growth, driven by "innovation + internationalization" trends, supported by policies and increasing global competitiveness [2] - The Innovative Pharmaceutical ETF (560900) has shown strong performance, with a 4.06% increase over the past week, and notable gains in constituent stocks such as Zhongsheng Pharmaceutical (10.02%) and Kelun Pharmaceutical (6.09%) [1] - Hengrui Medicine's debut on the Hong Kong stock market saw a significant opening increase of 29.4%, raising approximately HKD 9.9 billion, with plans to allocate 75% for R&D and 15% for expanding production facilities [1] Group 2 - The innovative pharmaceutical industry chain is showing signs of fundamental improvement, with recovery in overseas orders and performance, and domestic demand expected to rebound in 2025 [2] - The medical device sector is also anticipated to improve in 2025, alongside the emergence of AI in healthcare, which is expected to bring new changes to the pharmaceutical industry [2] - Morgan Asset Management is integrating its global technology investment products to help investors capitalize on opportunities in quality technology companies amid a new wave of technological advancements [2][3]

Core Viewpoint - The company, Kelun Pharmaceutical, is set to present six clinical research results at the 2025 American Society of Clinical Oncology annual meeting, showcasing advancements in cancer treatment [1] Group 1: Clinical Research Results - Kelun Biotech, a subsidiary of Kelun Pharmaceutical, will present data on antibody-drug conjugate Lukanasatuzumab targeting TROP2, monoclonal antibody Tagolisumab targeting PD-L1, and RET inhibitor KL590586 [1] - Lukanasatuzumab demonstrated a confirmed objective response rate of 45.1% in a randomized clinical study for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), with a median progression-free survival of 6.9 months [1] - Tagolisumab combined with gemcitabine and cisplatin showed a 53% reduction in the risk of disease progression or death in a randomized, double-blind Phase 3 clinical study for recurrent or metastatic nasopharyngeal carcinoma [1] - KL590586 achieved a confirmed objective response rate of 63.0% in a Phase I clinical study for patients with advanced RET gene mutation medullary thyroid carcinoma (MTC) [1]

证券代码：002422 证券简称：科伦药业 公告编号：2025-044 四川科伦药业股份有限公司 关于子公司在 2025 年美国临床肿瘤学会年会上 公布的六项创新药物研究成果的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）近日获悉，公司控股子公 司四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"）将于 2025 年 5 月 30 日至 6 月 3 日期间在美国伊利诺伊州芝加哥市举行的 2025 年美国临床肿瘤 学会(ASCO)年会上公布六项由科伦博泰主导的临床研究成果，包括其抗人滋养 细胞表面抗原 2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT)(佳泰 莱®)、抗程序性细胞死亡配体 1(PD-L1)单克隆抗体塔戈利单抗(tagitanlimab)(科泰 莱®)以及转染过程中重排(RET)抑制剂 KL590586（A400/EP0031）的相关数据。 具体研究情况如下： 1.芦康沙妥珠单抗(sac-TMT)用于经治的晚期表皮生长因子受体(EGFR)突变 非小细胞肺癌（NSCLC）患 ...

Group 1 - Qingmu Technology plans to reduce its shareholding by up to 3%, amounting to no more than 2.776 million shares [1] - Newcap received a decision from the police to revoke the case against its actual controller, who was previously detained for insider trading [2] - Rhine Biotech's directors and executives plan to collectively reduce their holdings by up to 0.14%, totaling no more than 1.0185 million shares [3] Group 2 - Puli Tui's stock and convertible bonds will be delisted on May 22, 2025 [5] - *ST Nong Shang will have its delisting risk warning lifted and will resume trading on May 23, 2025 [7] - State Grid Information Communication plans to acquire 100% equity of Yili Technology for approximately 1.853 billion yuan [9] Group 3 - Kelun Pharmaceutical's subsidiary received drug registration approval for a new injectable product, which is the first of its kind in China [10] - Aishida plans to acquire 7% equity of its subsidiary Zhejiang Qianjiang Robot Co., Ltd. for 13.09 million yuan [11] - Hongming Co. is planning to acquire 83% equity of Shenzhen Chisu Automation Equipment Co., Ltd. for approximately 151 million yuan [12] Group 4 - JuJiao Co. plans to reduce its shareholding by up to 2.6%, totaling no more than 2.093 million shares [14] - AVIC Financial's stock will be delisted on May 27, 2025 [16] - Jingwang Electronics' major shareholders plan to reduce their holdings by up to 2.99% [17] Group 5 - Huaren Health intends to acquire stakes in three pharmaceutical chain companies for a total of 327 million yuan [18] - Huanrui Century's original shareholders are required to compensate for unfulfilled performance commitments with 116 million shares [20] - Tefa Service's shareholders plan to reduce their holdings by up to 3% [21] Group 6 - Maipu Medical is planning to acquire at least 51% of Easy Medical's equity, which will constitute a major asset restructuring [22] - *ST Jinshi will have its delisting risk warning lifted and its stock will resume trading on May 23, 2025 [22] - Guoke Micro is planning a major asset restructuring and will suspend trading [23] Group 7 - Defu Technology intends to acquire 100% equity of an overseas electronic circuit copper foil company [24] - Xince Standard's shareholder plans to reduce its holdings by up to 1% [25] - Xiouqiang Co. plans to reduce its holdings by up to 3% [27]

证券代码：002422 证券简称：科伦药业 公告编号：2025-043 四川科伦药业股份有限公司 | 股东姓 | 是否为控股股 东或第一大股 | 本次解除质 | 占其所持股 | 占公司总股 | 起始日 | 解除日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 押股份数量 | | | | | | | 名 | 东及其一致行 | （股） | 份比例 | 本比例 | | | | | | 动人 | | | | | | | | 刘革新 | 是 | 2,673,000 | 0.71% | 0.17% | 2024/5/22 | 2025/5/22 | 华泰证券（上海） | | | | | | | | | 资产管理有限公司 | | 刘革新 | 是 | 1,280,000 | 0.34% | 0.08% | 2024/5/22 | 2025/5/22 | 华泰证券（上海） | | | | | | | | | 资产管理有限公司 | | 刘革新 | 是 | 2,781,000 | 0.73% | 0.17% | 2024/5/22 | 2025/5/ ...

Core Viewpoint - The trend of entrepreneurs personally endorsing their products has gained significant momentum, with notable figures like Liu Gexin of Kelun Pharmaceuticals showcasing their physical fitness to promote anti-aging products, reflecting a broader shift in branding strategies among business leaders [1][10]. Group 1: Entrepreneurial Branding - Entrepreneurs are increasingly adopting personal branding strategies, transforming themselves into "IP" (intellectual property) to enhance their companies' visibility and appeal [3][7]. - The phenomenon of entrepreneurs acting as brand ambassadors is not new, with historical examples dating back to the 1980s, such as Haier's Zhang Ruimin, who became a "celebrity entrepreneur" by publicly addressing product quality issues [8]. - Recent data indicates that Haier's overseas revenue grew by 13% year-on-year, highlighting the effectiveness of personal branding in driving business performance [8]. Group 2: Marketing Strategies - The marketing strategy of using entrepreneurs as brand ambassadors is seen as a cost-effective alternative to traditional celebrity endorsements, leveraging their personal stories to create a more relatable brand image [12]. - The approach of "body endorsement" is particularly impactful for health-related products, as demonstrated by Liu Gexin's promotion of Kelun's anti-aging capsules, which directly ties his fitness to the product's benefits [10][11]. - However, this strategy carries risks, as the personal image of the entrepreneur becomes closely linked to the brand, potentially leading to backlash if product controversies arise [12][14]. Group 3: Market Performance - Xiaomi reported a 35% year-on-year increase in total revenue for 2024, attributed in part to the personal branding efforts of its founder, Lei Jun, who has cultivated a fitness-oriented public persona [11]. - The market dynamics are shifting, with Xiaomi's smartphone market share rising to 16.8%, positioning it as the second-largest player in the domestic market, showcasing the effectiveness of its branding strategy [11]. - Despite the successes, the acceptance of high-priced health products, such as Kelun's anti-aging capsules priced at 1499 yuan per bottle, remains uncertain, indicating potential challenges in consumer acceptance [11]. Group 4: Consumer Engagement - The ultimate value of entrepreneur branding lies in building trust and emotional connections with consumers, rather than merely generating traffic or personal fame [15]. - Successful branding requires that products themselves are of high quality and meet consumer expectations, as exemplified by the challenges faced by high-priced products that do not resonate with buyers [15].

证券代码：002422 证券简称：科伦药业 公告编号：2025-042 四川科伦药业股份有限公司 关于子公司核心产品芦康沙妥珠单抗(sac-TMT)的新增适应症 上市申请(sNDA)获国家药品监督管理局受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 OptiTROP-Breast02 是一项随机、开放标签、多中心 3 期临床研究，评估芦 康沙妥珠单抗(sac-TMT)单一疗法(5mg/kg 每两周一次(Q2W))对比研究者选择化 疗方案用于治疗局部晚期或转移性 HR+/HER2- (免疫组织化学[IHC]0、IHC 1+或 IHC 2+/原位杂交[ISH]-) BC 患者的有效性和安全性。根据预设的期中分析，该 3 期临床研究达到主要疗效终点，与研究者选择化疗方案相比，芦康沙妥珠单抗 (sac-TMT)单一疗法在主要终点由盲态独立评审委员会(BIRC)评估的无进展生存 期(PFS)方面具有显著统计学意义和临床意义的改善，显著降低疾病进展或死亡 风险。同时，芦康沙妥珠单抗(sac-TMT)显示出总生存期(OS)获益趋势。 2025 年 5 月 16 ...

公开资料显示，工银前沿医疗股票C基金成立于2020年11月23日，截至2025年3月31日，工银前沿医疗 股票C规模13.80亿元，基金经理为赵蓓。 金融界2025年5月21日消息，工银前沿医疗股票C(010685) 最新净值2.9140元，增长1.53%。该基金近1个 月收益率4.11%，同类排名420|1001；近3个月收益率9.30%，同类排名81|988；今年来收益率13.47%， 同类排名116|978。 工银前沿医疗股票C股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8.01%）、XD药明康（7.72%）、百济神州-U（6.85%）、信立泰（4.90%）、泽璟制药-U （4.77%）、鱼跃医疗（4.60%）、新诺威（4.36%）、华东医药（4.20%）、海思科（3.53%）。 来源：金融界 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2 ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-041 四川科伦药业股份有限公司 关于公司注射用比阿培南/氯化钠注射液获得药品注册批准的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）子公司湖南科伦制药有限 公司的化学药品"注射用比阿培南/氯化钠注射液"于近日获得国家药品监督管 理局的药品注册批准，现将相关情况公告如下： 一、 药品基本情况 药品批准文号：国药准字H20254124 上市许可持有人：湖南科伦制药有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 2. 药品相关情况 1. 药品名称：注射用比阿培南/氯化钠注射液 剂型：注射剂 规格：粉体室：0.3g（按C15H18N4O4S计）；液体室100ml：氯化钠0.9 g 申请事项：药品注册（境内生产） 注册分类：化学药品3类 受理号：CYHS2303536 粉液双室袋是国际上先进的输液产品，其中粉体和液体分别位于两个独立的 腔室，保证混合前各腔室药品的稳定性， ...

Core Viewpoint - Kolon Pharmaceutical's subsidiary has received drug registration approval for its injectable product, marking a significant milestone in the domestic pharmaceutical market [1] Company Summary - Kolon Pharmaceutical (002422.SZ) announced that its subsidiary, Hunan Kolon Pharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration for its injectable drug "Injectable Biapenem/Sodium Chloride Injection" [1] - This product is the first of its kind in China to be approved in a dual-chamber bag packaging format [1] - The drug features a broad antibacterial spectrum, stability against β-lactamase, and strong antibacterial activity, while exhibiting lower nephrotoxicity and central nervous system toxicity [1]